(Q40164070)

English

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study (English)

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

relapsing-remitting multiple sclerosis

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Lahar Mehta

1

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Kimberly Umans

2

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Gulden Ozen

3

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Randy R Robinson

4

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Jacob Elkins

5

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

publication date

1 May 2017

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

International journal of MS care

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

19

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

3

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

141-147

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Dramatically changing rates and reasons for hospitalization in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Vaccination against infection in patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Quantitative review of antibody response to inactivated seasonal influenza vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

22 September 2017

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

25 September 2017

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

15 June 2018

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

20 August 2018

Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5460867

20 August 2018

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28603462

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a

1 reference

https://pubmed.ncbi.nlm.nih.gov/28603462

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humoral immune response to influenza vaccine in natalizumab-treated MS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28603462

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.7224/1537-2073.2016-026

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40164070&oldid=1887813011"